Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non‐muscle‐invasive bladder cancer: a randomised clinical trial

Miyata, Yasuyoshi; Tsurusaki, Toshifumi; Hayashida, Yoshiko; Imasato, Yushi; Takehara, Kosuke; Aoki, Daiyu; Nishikido, Masaharu; Watanabe, Junichi; Mitsunari, Kensuke; Matsuo, Tomohiro; Ohba, Kenkichi; Taniguchi, Keisuke; Sakai, Hideki

doi:10.1111/bju.15571

Cited by 9 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacillus Calmette‐Guerin is the first choice in intravesical perfusion treatment for intermediate‐risk or high‐risk NMIBC 8,9 . At present, advances have been achieved in perfusion times, perfusion period, and mechanism of action 10–13 .…”

Section: Discussionmentioning

confidence: 99%

“…Bacillus Calmette‐Guerin is the first choice in intravesical perfusion treatment for intermediate‐risk or high‐risk NMIBC. 8 , 9 At present, advances have been achieved in perfusion times, perfusion period, and mechanism of action. 10 , 11 , 12 , 13 However, the timing of the initial perfusion is still controversial, and uniform treatment guidelines are also lacking.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion

Cai,

Lu,

Chen

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveThere is no consensus regarding the best interval time between transurethral resection of a bladder tumor and Bacillus Calmette‐Guerin (BCG) perfusion. This study was to explore whether the interval time has an impact on the prognosis and adverse effects.MethodsWe retrospectively reviewed the clinical data of patients who received BCG intravesical perfusion at Sun Yat‐sen University Cancer Center (SYSUCC) from September 2015 to October 2021. Recurrence‐free survival (RFS) and progression‐free survival were the primary endpoints. Cox regression was used to explore independent predictors. The association between interval time and adverse effect grade was detected by logistic regression. Propensity score matching (PSM) was performed.ResultsA total of 403 patients were enrolled, the median interval time was 24 days (6–163 days), and the follow‐up was 28 months (7–82 months). Eighty‐eight (20.9%) patients relapsed, and 40 patients (10.0%) suffered progression. The multivariate Cox regression analysis confirmed that interval time was an independent predictor of RFS (p = 0.017). Notably, when the interval time was less than or equal to 26 days, there was a trend toward better RFS, PSM resulted in 65 matched pairs in each group, and Kaplan–Meier analysis showed that there was a significant difference in RFS between groups (p = 0.009). The logistic regression analysis showed that there was no correlation between interval time and adverse effects and their grades (p > 0.05).ConclusionsWe considered that the first BCG perfusion could be performed within 2–4 weeks after surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion

Cai,

Lu,

Chen

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…No matter how hard the current multidisciplinary treatment is, the high recurrence rate of BC is still the biggest obstacle for treatment. [116][117][118] The important role of exosomes-mediated signal transduction in cancer progression makes exosomes a potential new therapeutic target, which focuses on inhibiting the key components of the tumour cell communication network. Exosomes are expected to play an important role in the treatment of BC patients, help early diagnosis and monitoring and provide accurate predictive markers.…”

Section: Future E Xpec Tati On S Of E Xosome In Bcmentioning

confidence: 99%

The emerging roles of exosomal long non‐coding RNAs in bladder cancer

Liu

2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Bladder cancer (BC) is one of the most common malignant tumours of the genitourinary system, accounting for the 9th most common malignant tumour in the world. 1,2 According to pathological classification, 90% of patients with BC have urothelial cancer. About one-third of these patients are first diagnosed with muscle invasive bladder cancer (MIBC). 3,4 In some patients, even if the first diagnosis is non-muscle invasive bladder cancer (NMIBC), 10%-30% of patients progress to MIBC. 4,5 BC has become a disease that seriously affects human health. 6,7 At present, its early diagnosis and treatment have made great progress, 8,9 but its specific mechanism of occurrence and development is still unclear.In recent years, non-coding RNAs (ncRNAs) have become a research hotspot. NcRNAs can be divided into housekeeping ncRNAs and regulatory ncRNAs. Among them, regulatory ncRNAs can be mainly divided into microRNA (miRNA), long noncoding RNA (ln-cRNA) and circular RNA (circRNA). [10][11][12][13] LncRNA is a general term for single-stranded nucleotide sequences exceeding 200 bp. 14 Although it does not have the function of encoding proteins, it can participate in gene regulation at the epigenetic level, transcription level and post-transcriptional level, 15-17 affect tumour occurrence, development, metastasis and malignant progression of drug resistance. [18][19][20][21][22][23] Based on the current research on the mechanism of lncRNA, the competitive endogenous 'ceRNA' mechanism is the most common type and a widely recognized regulatory mechanism, that is, some

show abstract

“…Its cytotoxic effect results from DNA cross-linking, which inhibits DNA synthesis and cell proliferation. 16 While MMC is a well-established treatment for low-risk NMIBC, 17 its effectiveness in high-risk patients remains a point of contention, thereby necessitating further investigation.…”

Section: Introductionmentioning

confidence: 99%

Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer

Zaza,

Salem,

El-Sadat

et al. 2023

Urologia

View full text Add to dashboard Cite

Objectives: We aimed to compare the efficacy and adverse events of Bacillus Calmette-Guérin (BCG) versus Mitomycin C (MMC) in high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients. Methods: This randomized controlled study was conducted over 24 months in four hospitals in Egypt. A sample of 90 patients was randomly assigned to either treatment group, with procedures including baseline examinations, a single postoperative instillation of chemotherapy, a 6-week induction cycle of the assigned drug, and regular follow-up cystoscopies and upper urinary tract imaging. Treatment results and side effects were monitored, with data analyzed via Statistical Package for Social Sciences (SPSS). Results: No significant differences were observed in mean age or tumor characteristics ( p > 0.05). However, adverse reactions were significantly higher in the BCG group, including cystitis (40% vs. 17.78%, p = 0.020), hematuria (24.44% vs. 4.44%, p = 0.007), overall local reactions (75.56% vs. 26.67%, p < 0.001), fever (13.33% vs. 2.22%, p = 0.049), and fatigue (17.78% vs. 2.22%, p = 0.014). The MMC group had a slightly higher recurrence rate (28.89% vs. 17.78%, hazard ratio 1.89, 95% CI: 0.78–4.55, p = 0.15) with a shorter median time to recurrence (six vs. 12 months). Progression rates were similar (8.89% MMC vs. 4.44% BCG, p = 0.398). Conclusion: Although BCG and MMC have comparable efficacy in managing high-risk NMIBC, BCG demonstrated a higher rate of adverse reactions. Decision-making should consider this balance, patient preferences, and health status. Further research is needed for the validation and exploration of these findings.

show abstract

Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non‐muscle‐invasive bladder cancer: a randomised clinical trial

Cited by 9 publications

References 25 publications

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion

The emerging roles of exosomal long non‐coding RNAs in bladder cancer

Comparative study between mitomycin C versus Bacillus Calmette-Guérin (BCG) in high-risk non-muscle-invasive bladder cancer

Contact Info

Product

Resources

About